Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

NCT05024214 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Non-small Cell Lung Cancer
Renal Cell Carcinoma
Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib + Envafolimab
DRUG: Sunitinib

Sponsor

3D Medicines (Sichuan) Co., Ltd.